The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
 
Guilherme Rabinowits
Consulting or Advisory Role - Coherus Biosciences; Fennec Pharma; Fulgent Pharma; Merus
 
Christine Chung
Consulting or Advisory Role - AVEO; Bicara Therapeutics; Johnson & Johnson/Janssen; Regeneron
Research Funding - Acrivon Therapeutics (Inst); Regeneron (Inst)
 
Aditya Shreenivas
Consulting or Advisory Role - Bayer; Lilly; Taiho Pharmaceutical (Inst)
Research Funding - Caris Life Sciences (Inst); Foundation Medicine; Natera (Inst)
(OPTIONAL) Uncompensated Relationships - Datar Cancer Genetics
 
Eric Nadler
Consulting or Advisory Role - Merck; Novocure
Speakers' Bureau - AstraZeneca; EMD Serono; Jazz Pharmaceuticals; Pfizer
 
Donald Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Nabil Saba
Employment - Winship Cancer Institute
Honoraria - BMS; Coherus Biosciences; Exelixis; GlaxoSmithKline; Johnson & Johnson/Janssen; Medscape; Merck; Nanobiotix; Reddy Pharma Iberia; Summit Therapeutics; Surface Oncology
Consulting or Advisory Role - Akeso Biopharma
Research Funding - Bristol-Myers Squibb; Exelixis
Patents, Royalties, Other Intellectual Property - Springer textbook Royalty; Uptodate chapter writing and editing
Travel, Accommodations, Expenses - Merck
 
Ray Yin
Stock and Other Ownership Interests - Fulgent Genetics
 
Jorge Nieva
Leadership - AffyImmune Therapeutics
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L
Consulting or Advisory Role - AADi; ANP Technologies; AstraZeneca; Bioatla; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Pfizer; Takeda; Urogen pharma
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Jacob Thomas
Consulting or Advisory Role - Conjupro Biotherapeutics; Kura Oncology